Results 171 to 180 of about 253,218 (253)

Current and Emerging Therapeutic Strategies for the Treatment of Duchenne Muscular Dystrophy. [PDF]

Genes (Basel)
Lopez Perez MA, Weisleder NL.
europepmc   +1 more source

The Economic Burden of Duchenne Muscular Dystrophy: A Systematic Review. [PDF]

Pharmacoeconomics
Landfeldt E, Åberg M, Bello L, Deroo V, Born AP, Giusti S, Ekström AB.   +6 more
europepmc   +1 more source

Downstream Pathways of Dystrophin Deficiency in Duchenne Muscular Dystrophy: Implications for Muscle Degeneration and Regeneration. [PDF]

J Cachexia Sarcopenia Muscle
Epis R, Rovetta G, Ferrari G, Bonfanti C, Careccia G, Messina G.   +5 more
europepmc   +1 more source

Survey of Adrenal Insufficiency Management for Duchenne muscular dystrophy in Italy. [PDF]

Endocrine
Tornese G, Wong SC, Sbrocchi AM, De Angelis F, Zito I, Weber DR, Aversa T.   +6 more
europepmc   +1 more source

Functional assessments used in routine care for duchenne muscular dystrophy in the United States: A survey of certified duchenne care centers. [PDF]

J Neuromuscul Dis
Duvuru R, Camino E, Schrader R, Freed M, Signorovitch J, Zhong J, Bi S, Ward SJ, Veerapandiyan A.   +8 more
europepmc   +1 more source

Givinostat enhances antisense oligonucleotide efficacy in the <i>mdx52</i> model of Duchenne muscular dystrophy. [PDF]

Mol Ther Nucleic Acids
Phongsavanh X, Gastaldi C, Mottais A, Doisy M, Le Coz O, de Haan S, Spitali P, Garcia L, Goyenvalle A.   +8 more
europepmc   +1 more source

Duchenne muscular dystrophy coexisting with Down syndrome or Turner syndrome: Two case reports. [PDF]

World J Clin Pediatr
Pongsakornkullachart P, Chanvanichtrakool M, Dhachpramuk D, Pho-Iam T, Yongwattana N, Kulsirichawaroj P, Tanboon J, Sanmaneechai O.   +7 more
europepmc   +1 more source

Combination S100A1 and ARC gene therapy as a treatment for Duchenne muscular dystrophy cardiomyopathy. [PDF]

JCI Insight
Hammers DW, Hart CC, Zerpa E, Laurent KI, Lee YI, Sleeper MM, Sweeney HL.   +6 more
europepmc   +1 more source

Physical Activity and Quality of Life Among Caregivers of Children with Duchenne Muscular Dystrophy. [PDF]

Healthcare (Basel)
Yiğit S, Akgün İ, Coşkun K, Çınar MA, Usgu S, Perk P.   +5 more
europepmc   +1 more source

Five-Year Outcomes With Delandistrogene Moxeparvovec in Patients With Duchenne Muscular Dystrophy: A Phase 1/2a Study. [PDF]

Muscle Nerve
Mendell JR, Sahenk Z, Lowes LP, Iammarino MA, Alfano LN, McDonald CM, Signorovitch JE, Jin J, Li J, Mason S, Rodino-Klapac LR.   +10 more
europepmc   +1 more source